Lazard Asset Management
SANA icon

Lazard Asset Management’s Sana Biotechnology SANA Stock Holding History

Lazard Asset Management’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-132
Closed – – 2549
2024
Q4 		$0 Hold
132
– – ﹤0.01% 2507
2024
Q3 		$0 Sell
132
-198
-60% -$1.04K ﹤0.01% 2433
2024
Q2 		$1K Sell
330
-4,484
-93% -$35.7K ﹤0.01% 2178
2024
Q1 		$47K Sell
4,814
-2,663
-36% -$19.9K ﹤0.01% 1730
2023
Q4 		$29K Buy
7,477
+306
+4% +$1.13K ﹤0.01% 2017
2023
Q3 		$27K Buy
7,171
+321
+5% +$1.73K ﹤0.01% 2050
2023
Q2 		$40K Buy
6,850
+224
+3% +$1.29K ﹤0.01% 1900
2023
Q1 		$21K Buy
6,626
+3,984
+151% +$15.9K ﹤0.01% 2048
2022
Q4 		$10K Buy
+2,642
New +$12.9K ﹤0.01% 2200

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lazard Asset Management's SANA Position: Q1 2025 in Review

Lazard Asset Management sold out of Sana Biotechnology (SANA) in Q1 2025, closing a stake of 132 shares.

Lazard Asset Management first reported a position in SANA in Q4 2022 and held it in 9 quarters. The position peaked at $47K in Q1 2024. 161 funds tracked by Wall St. Rank hold SANA as of Q1 2025.

  • Lazard Asset Management reported no remaining Sana Biotechnology position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 132 Sana Biotechnology shares in Q1 2025.
  • Lazard Asset Management first reported a position in Sana Biotechnology in Q4 2022 and held it in 9 quarters.
  • Lazard Asset Management's Sana Biotechnology position peaked at $47K in Q1 2024.
  • 161 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.